New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections-Reference-Cited by-同舟云学术

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Published:2019-01 Issue:1 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Isler Burcu¹,Doi Yohei²,Bonomo Robert A.³⁴,Paterson David L.⁵

Affiliation:

1. Istanbul Education and Research Hospital, Istanbul, Turkey

2. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

3. Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA

4. Case Western Reserve University Veterans Affairs Center of Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA

5. The University of Queensland Centre for Clinical Research, Royal Brisbane and Women’s Hospital Campus, Brisbane, Queensland, Australia

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01110-18

Reference135 articles.

1. Acinetobacter baumannii : Emergence of a Successful Pathogen

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges

4. Impact of Carbapenem Resistance and Receipt of Active Antimicrobial Therapy on Clinical Outcomes of Acinetobacter baumannii Bloodstream Infections

5. Polymyxins Revisited

Cited by 240 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of the carbapenem-resistant Acinetobacter baumannii clinical reference isolate BAL062 (CC2:KL58:OCL1): resistance properties and capsular polysaccharide structure;mSystems;2024-09-10

2. An overview of sulbactam‐durlobactam approval and implications in advancing therapeutics for hospital‐acquired and ventilator‐associated pneumonia by acinetobacter baumannii‐calcoaceticus complex: A narrative review;Health Science Reports;2024-09

3. The impact and risk factors for developing pneumogenic bacteremia in carbapenem-resistant Acinetobacter baumannii nosocomial pneumonia in the intensive care unit: A multicenter retrospective study;International Journal of Infectious Diseases;2024-09

4. Acinetobacter baumannii transformants expressing oxacillinases and metallo-β-lactamases that confer resistance to meropenem: new tools for anti- Acinetobacter drug development and AMR preparedness;Antimicrobial Agents and Chemotherapy;2024-08-27

5. In Vitro and In Vivo Studies on a Mononuclear Ruthenium Complex Reveals It is a Highly Effective, Fast-Acting, Broad-Spectrum Antimicrobial in Physiologically Relevant Conditions;ACS Infectious Diseases;2024-08-06